Lazertinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 148 publications
Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
Journal: Journal of medical economics
Published: April 13, 2026
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 23, 2026
Real-world occurrence of severe gastrointestinal bleeding in patients receiving amivantamab plus lazertinib: A two-case series among 25 consecutive cases.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 19, 2026
Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC.
Journal: Cancer research and treatment
Published: December 23, 2025
Prevention and Management of Dermatologic Adverse Events in Patients Treated with Amivantamab Plus Lazertinib.
Journal: Current oncology (Toronto, Ont.)
Published: December 21, 2025
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025
Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option?
Journal: Current oncology (Toronto, Ont.)
Published: December 01, 2025
Response to the Letter to the Editor: "Lazertinib in EGFR-Mutated NSCLC with CNS Metastases: Reinforcing the Role of Third-Generation TKIs through Pooled Analysis".
Journal: Clinical lung cancer
Published: November 14, 2025
Rapidly evolving therapeutic advances for classical EGFR-mutant NSCLC.
Journal: Frontiers in oncology
Published: October 25, 2025
Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study.
Journal: Translational lung cancer research
Published: October 25, 2025
Solid phase extraction and high-performance liquid chromatographic determination of lazertinib in human plasma.
Journal: Drug discoveries & therapeutics
Published: October 19, 2025
Last Updated: 04/28/2026